OPCH — Option Care Health, Inc.

Option Care Health (OPCH) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $1.4 billion, up 1% year-over-year, but below expectations.
• Adjusted EBITDA: $105 million, down 6% from the prior year, in line with expectations.
• Adjusted EPS: $0.40, flat compared to the previous year.
• Gross Profit: Slight decline attributed to chronic therapy revenue drop.
• Operating Cash Flow: Usage of $12 million, typical for Q1 due to seasonality.
• Net Debt to Leverage Ratio: 2.2x.
• SG&A Expenses: Grew 4% due to investments in commercial resources.

2. Strategic Updates and Business Highlights

• Acute Therapy Growth: High single-digit growth driven by strong execution and partnerships with hospitals and health systems.
• Chronic Therapy Challenges: Slight decline in revenue due to unexpected resets in patient census and therapy mix, particularly in the Chronic Inflammatory Disease (CID) portfolio.
• Patient Satisfaction: Continued high satisfaction scores in the low 90s and Net Promoter Scores in the mid-70s.
• Commercial Strategy: Focus on increasing the size and strength of the commercial team, enhancing operational excellence, and refining the go-to-market model.
• Ambulatory Infusion Clinics: 14% year-over-year growth in visits, with 28 operational locations.

3. Forward Guidance and Outlook

• Revised Full-Year Revenue Guidance: $5.675 billion to $5.775 billion, reflecting a negative 600 basis point headwind primarily from CID portfolio challenges.
• EBITDA Guidance: Maintained at $480 million to $505 million.
• Adjusted EPS Guidance: Maintained at $1.82 to $1.92.
• Q2 Expectations: Anticipated mid-single-digit revenue growth with high single-digit EBITDA growth sequentially.

4. Bad News, Challenges, or Points of Concern

• Revenue Growth Shortfall: Q1 revenue growth of only 1% did not meet expectations, primarily due to a decline in chronic therapy revenue.
• CID Portfolio Headwinds: Increased gross profit headwind from $25-35 million to $55 million due to unexpected patient census loss and unfavorable therapy mix.
• Competitive Pressures: Notable loss of patients to competitors, particularly in the context of changing health plans and formulary management.
• Operational Challenges: Increased administrative workload related to benefit reverification and authorizations delayed patient transitions and approvals.

5. Notable Q&A Insights

• Patient Loss: Management acknowledged losing patients to competitors due to higher standards set by payers and preferred biosimilars.
• Market Dynamics: The first quarter was particularly challenging due to significant changes in Medicare Advantage plans and insurance formulary dynamics.
• Confidence in Recovery: Management expressed confidence in rebuilding the patient census and achieving sequential growth in Q2 and beyond, emphasizing the strength of the acute therapy segment.
• Cost Management: Plans to manage costs effectively, including reductions in variable operating costs and incentive compensation, while maintaining investments in growth.
• M&A and Capital Deployment: Commitment to pursuing M&A opportunities and periodic share buybacks while prioritizing organic growth investments.

Overall, while Option Care Health faced challenges in Q1 2026, particularly in chronic therapies, management remains focused on strategic initiatives to drive recovery and growth moving forward.